3 Medicine Store Chain, Borax Producer and Dairy Brand Stocks With a Strong Future Roadmap: Medplus Health Services, Indo Borax & Chemicals and Heritage Foods

Medplus Rs 611.95, P/E 36.06. Indo Borax Rs 472.40, P/E 27.49. Heritage Foods Rs 405.40, P/E 26.48. Closing prices of 14 Oct 2026.

Updated: 19 Oct 2026 • 4:16 pm

Posted by:

Quick Answer

Medicine store chain, borax producer and dairy brand stocks with the clearest long-term roadmaps today include Medplus in a pharmacy retail chain with stores across several states, Indo Borax in boron-based chemicals such as boric acid and borax used in glass, ceramics and agriculture and Heritage Foods in milk, curd and value-added dairy products sold across southern and other states. FY26 revenue growth was 12.6% at Medplus, 21.0% at Indo Borax and 9.3% at Heritage Foods. P/E stands at 36.06 for Medplus (industry 66.59), 27.49 for Indo Borax (industry 36.60) and 26.48 for Heritage Foods (industry 34.85). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company's risks need equal attention.

Medicine store chain, borax producer and dairy brand stocks give investors exposure to medicines, specialty chemicals and dairy. Volumes, pricing and margins decide how much of that demand turns into profit.

This list covers three medicine store chain, borax producer and dairy brand stocks: Medplus Health Services for a pharmacy retail chain with stores across several states, Indo Borax & Chemicals for boron-based chemicals such as boric acid and borax used in glass, ceramics and agriculture and Heritage Foods for milk, curd and value-added dairy products sold across southern and other states. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

Table of Contents

What Are Medicine Store Chain, Borax Producer and Dairy Brand Stocks?

Medicine store chain, borax producer and dairy brand stocks are shares of companies that make health products, chemicals or run restaurants. Results depend on volumes, store additions and margins, so margins and cash flow separate the stronger names.

Medicine Store Chain, Borax Producer and Dairy Brand Stocks at a Glance

The table compares size, valuation, return on equity and debt for the three medicine store chain, borax producer and dairy brand stocks as of the 14 Oct 2026 close.

Company	CMP (Rs)	Market Cap (Rs Cr)	P/E	Industry P/E	ROE	Debt to Equity
Medplus Health Services	611.95	7,589	36.06	66.59	11.12%	0.72
Indo Borax & Chemicals	472.40	1,548	27.49	36.60	11.09%	0.00
Heritage Foods	405.40	3,562	26.48	34.85	13.61%	0.33

Among healthcare and consumer stocks, all three trade at a discount to their industry P/E multiples.

Why Do Medicine Store Chain, Borax Producer and Dairy Brand Stocks Have a Strong Roadmap in India?

Medicine store chain, borax producer and dairy brand stocks have a strong roadmap in India because medicine retail, glass and farm chemical demand and packaged dairy keep adding volumes for these firms. Three drivers stand out.

Medicine retail: Families buy medicines from store chains.
Chemical demand: Glass, ceramic and farm users buy boron chemicals.
Packaged dairy: Households buy milk, curd and dairy products.

Medplus Health Services: Pharmacy Retail Stores Anchor the Roadmap

Medplus' roadmap rests on a pharmacy retail chain with stores across several states, with store expansion supporting revenue.

Revenue grew from Rs 3,810.64 crore in FY22 to Rs 6,963.79 crore in FY26, an 82.7% rise, and FY26 revenue was 12.6% higher than FY25. FY26 net profit rose 46.2% to Rs 219.61 crore. Over four years, net profit rose from Rs 94.72 crore in FY22 to Rs 219.61 crore. In Q1 FY27, revenue grew 21.9% to Rs 1,899.43 crore. Operating margin was 9.85% in FY26.

Debt to equity is 0.72 and return on equity is 11.12%. FY26 operating cash flow was Rs 495.58 crore against capital expenditure of Rs 123.03 crore. At a P/E of 36.06 against an industry P/E of 66.59, the stock trades below its industry multiple.

What to watch: Net profit margin is only 3.2%, so small cost changes move earnings.

Indo Borax & Chemicals: Boron Chemicals Anchor the Roadmap

Indo Borax's roadmap rests on boron-based chemicals such as boric acid and borax used in glass, ceramics and agriculture, with wide industrial usage supporting volumes.

Revenue grew from Rs 178.93 crore in FY22 to Rs 230.89 crore in FY26, a 29.0% rise, and FY26 revenue was 21.0% higher than FY25. FY26 net profit rose 18.3% to Rs 50.27 crore. Over four years, net profit rose from Rs 36.37 crore in FY22 to Rs 50.27 crore. In Q1 FY27, revenue grew 28.9% to Rs 72.92 crore, and net profit rose 59.3% to Rs 16.25 crore. Operating margin was 27.28% in FY26 and 31.78% in Q1 FY27 against 28.43% a year earlier.

Debt to equity is 0.00 and return on equity is 11.09%. FY26 operating cash flow was Rs 87.15 crore against capital expenditure of Rs 0.29 crore. Indo Borax paid a dividend of Rs 1 per share for FY26, a yield of 0.21%. At a P/E of 27.49 against an industry P/E of 36.60, the stock trades below its industry multiple.

What to watch: Q1 FY27 operating margin was 31.78% against 27.28% for FY26, so margin stability is the figure to follow as volumes grow.

Heritage Foods: Value-Added Dairy Drives the Pipeline

Heritage Foods' roadmap rests on milk, curd and value-added dairy products sold across southern and other states, with branded dairy demand supporting volumes.

Revenue grew from Rs 2,692.55 crore in FY22 to Rs 4,550.22 crore in FY26, a 69.0% rise, and FY26 revenue was 9.3% higher than FY25. FY26 net profit was Rs 150.14 crore. In Q1 FY27, revenue grew 17.7% to Rs 1,344.50 crore. Operating margin was 5.86% in FY26.

Debt to equity is 0.33 and return on equity is 13.61%. FY26 operating cash flow was Rs 237.18 crore against capital expenditure of Rs 382.39 crore. Heritage Foods paid a dividend of Rs 2.5 per share for FY26, a yield of 0.65%. At a P/E of 26.48 against an industry P/E of 34.85, the stock trades below its industry multiple.

What to watch: Net profit margin is only 3.3%, so small cost changes move earnings.

Best Medicine Store Chain, Borax Producer and Dairy Brand Stocks in India: Medplus vs Indo Borax vs Heritage Foods on Key Financials

Among the best medicine store chain, borax producer and dairy brand stocks in India, Medplus ranks second on FY26 revenue growth and FY26 operating margin; Indo Borax leads on FY26 revenue growth and FY26 operating margin; Heritage Foods leads on return on equity and the lowest P/E. The table puts the numbers side by side.

Metric	Medplus	Indo Borax	Heritage Foods
FY26 revenue (Rs Cr)	6,963.79	230.89	4,550.22
FY26 revenue growth	12.6%	21.0%	9.3%
FY26 net profit (Rs Cr)	219.61	50.27	150.14
FY26 operating profit margin	9.85%	27.28%	5.86%
Q1 FY27 revenue growth (YoY)	21.9%	28.9%	17.7%
Return on equity	11.12%	11.09%	13.61%
P/E ratio	36.06	27.49	26.48
Debt to equity	0.72	0.00	0.33
Dividend yield	0.00%	0.21%	0.65%
FY26 operating cash flow (Rs Cr)	495.58	87.15	237.18

Healthcare, chemicals and food earnings follow volumes, store additions and margins, so full-year numbers and quarterly trends together give a better view.

How to Evaluate Medicine Store Chain, Borax Producer and Dairy Brand Stocks to Buy Before You Invest

A short checklist keeps the research consistent when you screen medicine store chain, borax producer and dairy brand stocks and shortlist medicine store chain, borax producer and dairy brand stocks to buy.

Compare each stock's P/E with its industry P/E, which differs by company here.
Check revenue growth, operating margin and cash flow together.
Check whether revenue growth is turning into profit growth, not only sales.
Read operating cash flow against capital expenditure to see how growth is funded.
Watch debt to equity and interest cover before sizing a position.
Spread exposure across companies and business lines instead of one demand cycle.

Check the Univest Screener for live data on these medicine store chain, borax producer and dairy brand stocks

Risks to Consider Before Investing in Medicine Store Chain, Borax Producer and Dairy Brand Stocks

Consumer demand: Spending patterns can shift sales between quarters.
Input costs: Changes in raw material prices can affect margins.
Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.

Download the Univest iOS App or Univest Android App to track Medplus, Indo Borax and Heritage Foods live.

Final Take: Which Stock Has the Strongest Roadmap?

These three healthcare and consumer stocks cover a pharmacy chain, a chemical maker and a dairy company. Medplus ranks second on FY26 revenue growth and FY26 operating margin; Indo Borax leads on FY26 revenue growth and FY26 operating margin; Heritage Foods leads on return on equity and the lowest P/E.

Across medicine store chain, borax producer and dairy brand stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the medicine store chain, borax producer and dairy brand stocks to buy discussed here.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on Medicine Store Chain, Borax Producer and Dairy Brand Stocks

Which are the best medicine store chain, borax producer and dairy brand stocks in India with a strong roadmap?

Ans. Medplus Health Services, Indo Borax & Chemicals and Heritage Foods stand out for their roadmaps in a pharmacy chain, a chemical maker and a dairy company. FY26 revenue growth was 12.6% at Medplus, 21.0% at Indo Borax and 9.3% at Heritage Foods, and return on equity ranges from 11.09% to 13.61%.

Is Medplus Health Services a good stock to buy now?

Ans. Medplus Health Services has a debt to equity ratio of 0.72, a return on equity of 11.12% and a P/E of 36.06 against an industry P/E of 66.59. Valuation, demand and input costs move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.

What is the P/E ratio of Medplus, Indo Borax and Heritage Foods?

Ans. The P/E ratio is 36.06 for Medplus (industry 66.59), 27.49 for Indo Borax (industry 36.60) and 26.48 for Heritage Foods (industry 34.85). All of them trade below the industry multiple.

Which of these medicine store chain, borax producer and dairy brand stocks has the highest return on equity?

Ans. Heritage Foods has the highest return on equity at 13.61%, followed by Medplus Health Services at 11.12% and Indo Borax & Chemicals at 11.09%.

What are the risks of investing in medicine store chain, borax producer and dairy brand stocks?

Ans. The main risks are consumer demand, input costs and quarterly trends. Spending patterns can shift sales between quarters.

How did Medplus, Indo Borax and Heritage Foods perform in Q1 FY27?

Ans. Medplus Health Services reported revenue of Rs 1,899.43 crore, up 21.9% year on year. Indo Borax & Chemicals reported revenue of Rs 72.92 crore, up 28.9% year on year, and net profit rose 59.3% to Rs 16.25 crore. Heritage Foods reported revenue of Rs 1,344.50 crore, up 17.7% year on year.

Do medicine store chain, borax producer and dairy brand stocks pay dividends?

Ans. Indo Borax and Heritage Foods pay dividends. The dividend yield is 0.21% for Indo Borax and 0.65% for Heritage Foods, based on dividends declared for FY26.

How can I invest in medicine store chain, borax producer and dairy brand stocks in India?

Ans. You can buy medicine store chain, borax producer and dairy brand stocks through a demat and trading account on NSE or BSE after checking each company's financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.